免疫肿瘤治疗开发的创新浪潮

下一代细胞疗法和精准免疫疗法推动成长和新产品开发

免疫肿瘤学 (IO) 疗法透过利用宿主的免疫系统来靶向肿瘤。随着各种类型的进行性和难治性癌症的发病率和盛行率不断增加，下一代 IO 治疗的管道正在经历显着增长。嵌合体标靶抗体疗法，包括嵌合抗原受体（CAR）-T细胞疗法、单株、抗体药物复合体（ADC）、双特异性抗体和一些治疗性癌症疫苗，提供有效的免疫，在临床试验中取得了快速进展一种疗法。本研究讨论了推动此类 IO 治疗发展的主要趋势和技术。我们探索针对各种癌症适应症的癌症疫苗和细胞疗法的进展，并重点介绍该领域的一些创新企业。也讨论了下一代细胞疗法、个人化癌症疫苗和战略重点领域。这项研究检验了该行业的驱动因素和阻碍因素，并确定了市场参与企业和相关人员应利用的该行业变化带来的成长机会。

本次调查回答的主要问题

• 目前IO治疗的临床现况如何？
• 推动 IO 治疗采用的技术推动因素是什么？
• 过继性细胞疗法和癌症疫苗的关键进展是什么？
• 临床成功应用的障碍是什么？
• 研究和开发的优先领域是什么？
• 您未来的重点领域是什么？

目录

战略问题

• 为什么成长如此困难？策略要务 8 (TM)：限製成长的因素
• The Strategic Imperative 8（TM）
• 三大策略重要性对免疫肿瘤 (IO) 治疗产业的影响
• 成长机会是Growth Pipeline Engine（TM）
• 调查方法

生长环境：IO处理

• 免疫治疗需求
• 分析范围
• 分段IO处理简介
• IO治疗正在开发中
• IO 治疗的成长机会
• 生长促进因子
• 成长抑制因素

趋势与研发重点：IO 治疗

• IO技术的趋势与发展
• IO 治疗的趋势
• IO治疗发展趋势
• 支持免疫疗法的优先研究和开发领域
• TME 的监管：固体癌类型决定治疗方法
• 发展实用化的有效临床前模型
• IO 治疗评估临床前模型开发的相关人员
• 整体肿瘤分析加速精准肿瘤学工作

IO新疗法的发展形势

• IO 治疗概述
• IO治疗的临床发展现状
• 细胞疗法推动下一波 IO 发展
• 细胞疗法类型简介
• IO细胞疗法的临床发展现状
• 细胞疗法的新重点领域，可提高功能性和安全性
• 下一代CAR-T疗法的开发
• 提高细胞免疫治疗可及性的优先领域
• 细胞疗法製造和交付的创新技术
• 相关人员开发新的下一代细胞疗法
• 疫苗应对难以治疗的癌症挑战的潜力
• 癌症疫苗的类型
• 临床开发中的个人化新抗原疫苗
• 加强癌症疫苗研发的重点领域
• RNA疫苗正在推动预防性和治疗性癌症疫苗的浪潮
• 癌症疫苗和免疫疗法的未来
• 新出现的癌症疫苗
• 新兴癌症疫苗对每种癌症的影响

IO相关人员生态系统

• IO 开发与采用的区域趋势
• 加速 IO 治疗开发的联邦倡议和计划
• IO交易及投资趋势
• 2023 年 IO 领域着名的合作伙伴关係与联盟

IO法规环境和报销

• IO：当前差距和潜在机会
• 改善 IO 治疗和护理服务可近性的策略

成长机会宇宙

• 成长机会1：联合免疫治疗
• 成长机会2：精准肿瘤学
• 成长机会三：先进合成生物学平台
• 成长机会4：类器官与器官晶片模型

附录

• 核准的ADC 列表
• 核准的CAR-T 疗法（全球）

下一步

Next-gen Cell Therapies and Precision Immunotherapies are Driving Growth and New Product Development

Immuno-oncology (I-O) therapies target tumors by harnessing the host's immune system. With the growing incidence and prevalence of various types of aggressive and refractory cancers, the next-generation I-O therapy pipeline has witnessed significant growth. Chimeric antigen receptor (CAR)-T cell therapy and tumor-targeted antibody therapies, including monoclonals, antibody-drug conjugates (ADCs), bispecific antibodies, and several therapeutic cancer vaccines, are making rapid strides in clinical trials as effective immunotherapy. This study discusses the key trends and technologies driving the development of such I-O therapies. It delves into advancements in cancer vaccines and cell therapies for various cancer indications, highlighting some of the innovators in this space. Next-generation cell therapies, personalized cancer vaccines, and strategic areas of focus have also been discussed in this report. The study examines the factors driving and restraining this industry and identifies the growth opportunities emerging from the changes in this space for market players and stakeholders to leverage.

Key questions answered in this study:

•      What does the current clinical landscape of I-O therapies look like?
•      Which are the technology enablers driving the adoption of I-O therapies?
•      What are the key developments in adoptive cell therapies and cancer vaccines?
•      What are the roadblocks to successful translation?
•      What are the research and development (R&D) focus areas?
•      What are the key focus areas for the future?

Table of Contents

Strategic Imperatives

• Why Is It Increasingly Difficult to Grow? The strategic imperative 8™: Factors creating pressure on growth
• The Strategic Imperative 8™
• The Impact of the Top 3 Strategic Imperatives on the Immuno-Oncology (I-O) Therapeutics Industry
• Growth Opportunities Fuel the Growth Pipeline Engine™
• Research Methodology

Growth Environment: I-O Therapies

• Need for Immunotherapy
• Scope of Analysis
• Segmentation: Snapshot of I-O Therapies
• I-O Therapies in Development
• Growth Opportunities in I-O Therapy
• Growth Drivers
• Growth Restraints

Trends and R&D Focus: I-O Therapies

• I-O Technology Trends and Developments
• Trends in I-O Therapeutics
• Therapeutic Development Trends in I-O
• R&D Focus Areas to Boost Immunotherapies
• Modulation of TME: Solid Tumor Type Determines Therapy
• Developing Effective Preclinical Models for Translation
• Stakeholders Developing Preclinical Models for I-O Therapy Evaluation
• Holistic Tumor Profiling to Boost Precision Oncology Efforts

Emerging I-O Therapeutic Modality Development Landscape

• Quick Facts on I-O Therapies
• Clinical Development Landscape of I-O Therapies
• Cell Therapy to Create the Next Wave of I-O Developments
• Cell Therapy Types: Snapshot
• Clinical Development Landscape of I-O Cell Therapies
• Emerging Areas of Focus to Improve Functionality and Safety Cell Therapies
• Next-generation CAR-T Therapy Development
• Priority Areas to Improve the Accessibility of Cell Immunotherapy
• Innovative Technologies for Cell Therapy Manufacturing and Delivery
• Stakeholders Developing Emerging Next-gen Cell Therapies
• Potential of Vaccines to Address Challenges with Difficult-to-Treat Cancers
• Cancer Vaccine Types
• Personalized Neoantigen Vaccines in Clinical Development
• Areas of Focus to Bolster Cancer Vaccine Development
• RNA Vaccines to Drive the Wave of Prophylactic and Therapeutic Cancer Vaccines
• Road Ahead for Cancer Vaccines and Immunotherapy
• Emerging Cancer Vaccine
• Impact of Emerging Cancer Vaccines Across Cancers

I-O Stakeholder Ecosystem

• Regional Trends in I-O Developments and Adoption
• Federal Initiatives and Programs Driving I-O Therapy Development
• I-O Deals and Investment Trends
• Notable Partnerships and Collaborations in I-O, 2023

I-O Regulatory Environment and Reimbursement

• I-O: Current Gaps and Potential Opportunities
• Strategies to Improve Access and Care Delivery of I-O Therapies

Growth Opportunity Universe

• Growth Opportunity 1: Combination Immunotherapies
• Growth Opportunity 2: Precision Oncology
• Growth Opportunity 3: Advanced Synthetic Biology Platforms
• Growth Opportunity 4: Organoids and Organ-on-Chip Models

Appendix

• List of a Few Approved ADCs
• Approved CAR-T Therapies (global)

Next Steps

• Your Next Steps
• Why Frost, Why Now?
• Legal Disclaimer